Cartesian Therapeutics Inc
NASDAQ:RNAC

Watchlist Manager
Cartesian Therapeutics Inc Logo
Cartesian Therapeutics Inc
NASDAQ:RNAC
Watchlist
Price: 6.72 USD -6.93%
Market Cap: 174.7m USD

Wall Street
Price Targets

RNAC Price Targets Summary
Cartesian Therapeutics Inc

Wall Street analysts forecast RNAC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RNAC is 35.99 USD with a low forecast of 16.16 USD and a high forecast of 46.2 USD.

Lowest
Price Target
16.16 USD
140% Upside
Average
Price Target
35.99 USD
436% Upside
Highest
Price Target
46.2 USD
588% Upside
Cartesian Therapeutics Inc Competitors:
Price Targets
URGN
Urogen Pharma Ltd
56% Upside
TLX
Telix Pharmaceuticals Ltd
127% Upside
NTRA
Natera Inc
4% Upside
IKT
Inhibikase Therapeutics Inc
244% Upside
6628
Transcenta Holding Limited
553% Upside
TGTX
TG Therapeutics Inc
46% Upside
196170
Alteogen Inc
23% Upside
CSL
CSL Ltd
39% Upside

Revenue
Forecast

Revenue Estimate
Cartesian Therapeutics Inc

For the last 9 years the compound annual growth rate for Cartesian Therapeutics Inc's revenue is 23%. The projected CAGR for the next 4 years is -11%.

23%
Past Growth
-11%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Cartesian Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
6%
Average Beat

Net Income
Forecast

Net Income Estimate
Cartesian Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-90%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RNAC's stock price target?
Price Target
35.99 USD

According to Wall Street analysts, the average 1-year price target for RNAC is 35.99 USD with a low forecast of 16.16 USD and a high forecast of 46.2 USD.

What is Cartesian Therapeutics Inc's Revenue forecast?
Projected CAGR
-11%

For the last 9 years the compound annual growth rate for Cartesian Therapeutics Inc's revenue is 23%. The projected CAGR for the next 4 years is -11%.

Back to Top